2025. Characterization of ORKA-001, a Novel Extended Half-life Monoclonal Antibody Targeting IL-23 for the Treatment of Psoriasis. SKIN The Journal of Cutaneous Medicine. 9, 2 (Mar. 2025), s527. DOI:https://doi.org/10.25251/skin.10.supp.527.